Navigation Links
Senetek PLC Reports 2007 Financial Results
Date:4/15/2008

dial-in number is 877-593-8638; the international dial-in number is 706-634-9240, conference ID: 43869518. Replay of the conference call will be available until April 30, 2008. Domestic Replay dial-in 800-642-1687, International Replay dial-in 706-645-9291, replay conference ID: 43869518.

About Senetek PLC:

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward- looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future event
'/>"/>

SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
2. Senetek PLC Announces Launch of New Website
3. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
4. Senetek PLC Reports Third Quarter 2007 Financial Results
5. Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
6. Exponent Reports First Quarter 2008 Results
7. J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience
8. Marijuana use on the rise among Ontario adults, CAMH reports
9. Longs Reports Preliminary March Retail Drug Store Sales
10. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
11. IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 26, 2014 2014 ... Gel Permeation Chromatography Industry” is a professional ... and China Gel Permeation Chromatography market. The ... including Gel Permeation Chromatography definition, classification, application, ... industry overview. This research covers the international ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... dismissal and summary judgment in two DePuy Pinnacle hip ... paving the way for the claims to go before ... reports. In an opinion rendered on July 18th, U.S. ... Texas, ruled that the two Plaintiffs’ claims may proceed ...
(Date:7/25/2014)... are more easily distracted during thinking and memory tasks ... any type of memory test administered reveals a decline ... co-author Randi Martin, professor of psychology at Rice University, ... said, this study shows that "environmental interference" has a ... younger adults. The study included 60 seniors, aged ...
(Date:7/25/2014)... As reported by People Magazine in the article Mike ... Sober (7/15), one of the most popular cast stars ... the public about his personal transformation. Now, two years later ... moving on with his life was a challenge. He was ... 2012 and even spent some time in rehab. He took ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
Breaking Medicine News(10 mins):Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Distractions Seem More Troublesome With Age 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2
... , , FREMONT, Calif., Nov. 24 ... today announced the launch of the VersaWave(R) Specialty Er:YAG all-issue dental ... Greater New York Dental Meeting, November 30 - December 3, 2008 ... , "The VersaWave Specialty builds on our solid heritage ...
... results yesterday evaluating the Novo-TTF device in vitro ... the device enhanced the efficacy of standard chemotherapy ... When used in combination with standard chemotherapy, the ... intensity alternating electric fields to destroy cancer cells, ...
... and Transportation System Reduces Endoscope Cross-contamination and Protects Scopes ... New Infection Prevention Solution for Busy GI Suites , ... 24 Advanced Sterilization Products (ASP), division of Ethicon ... CLEANASCOPE System, a new infection prevention solution designed to ...
... , , MONDAY, Nov. 24 (HealthDay News) -- The interaction between ... may contribute to epileptic seizures, new research suggests. , If ... be a target for new treatments or even preventive measures ... of Nature Medicine . , "This opens a window ...
... Recognized - , , WASHINGTON, Nov. ... definitive voice for 50+ Americans and the world,s largest-circulation magazine with ... Inspire Awards . The Inspire Awards pay tribute ... innovative thinking, passion and perseverance. The 2009 honorees include Glenn ...
... developer of,LifeShirt(R), a continuous, integrated and wearable remote ... proprietary LifeShirt(R),system is being used by Concordia ... factors that may put children at risk for ... Children enrolled in ...
Cached Medicine News:Health News:HOYA ConBio(TM) Introduces VersaWave(R) Specialty Laser 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 3Health News:ASP Announces Availability of CLEANASCOPE System 2Health News:Clue to Cause of Epileptic Seizures Discovered 2Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 2Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 3Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 4Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 5Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 6Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 7Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 8Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 2Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 3Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 4
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... BUENA, N.J. , July 24, 2014 ... New Jersey based specialty generic pharmaceutical company, ... resignation from its Board of Directors.  Mr. Finio has ... company, and under the terms of his acceptance of ... continue in his role as Director for IGI Laboratories, ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Results,published this week in The Lancet show that ... 6, 11,16, 18) Recombinant Vaccine) was 100 percent ... by HPV,types 16 and 18, two types strongly ... observed in women who were not,infected with HPV ...
... at 9th International Symposium on,Myelodysplastic Syndromes, TAMPA, Fla., ... a pivotal Phase II trial evaluating Revlimid in ... syndromes (MDS),were presented today by Dr. Alan List, ... Institute, at the 9th International,Symposium on MDS currently ...
Cached Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3